Order Article Reprints

Popadiuk C, Gauvreau CL, Bhavsar M, Nadeau C, Asakawa K, Flanagan WM, Wolfson MC, Coldman AJ, Memon S, Fitzgerald N, et al. Using the Cancer Risk Management Model to Evaluate the Health and Economic Impacts of Cytology Compared with Human Papillomavirus DNA Testing for Primary Cervical Cancer Screening in Canada. Current Oncology. 2016; 23(s1):56-63. https://doi.org/10.3747/co.23.2991

Popadiuk, C., C.L. Gauvreau, M. Bhavsar, C. Nadeau, K. Asakawa, W.M. Flanagan, M.C. Wolfson, A.J. Coldman, S. Memon, N. Fitzgerald, and et al. 2016. "Using the Cancer Risk Management Model to Evaluate the Health and Economic Impacts of Cytology Compared with Human Papillomavirus DNA Testing for Primary Cervical Cancer Screening in Canada" Current Oncology 23, no. s1: 56-63. https://doi.org/10.3747/co.23.2991

Popadiuk, C., Gauvreau, C. L., Bhavsar, M., Nadeau, C., Asakawa, K., Flanagan, W. M., Wolfson, M. C., Coldman, A. J., Memon, S., Fitzgerald, N., Lacombe, J., & Miller, A. B. (2016). Using the Cancer Risk Management Model to Evaluate the Health and Economic Impacts of Cytology Compared with Human Papillomavirus DNA Testing for Primary Cervical Cancer Screening in Canada. Current Oncology, 23(s1), 56-63. https://doi.org/10.3747/co.23.2991